Jasper Therapeutics (JSPR) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

JSPR Jasper Therapeutics

Watchlist

21.570
+0.040+0.19%

Close Dec 20 16:00 ET

21.570
0.0000.00%

Post 18:05 ET

323.58MMarket Cap-4.54P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Jasper Launches AI Studio, Empowering Enterprise Marketing Teams to Build & Scale Generative AI Solutions
PR NewswireDec 16 09:00 ET
Insider Sale: Chief Operating Officer of $JSPR (JSPR) Sells 900 Shares
Quiver QuantitativeDec 12 20:16 ET
BMO Capital Initiates Coverage On Jasper Therapeutics With Outperform Rating, Announces Price Target of $63
BenzingaDec 6 05:50 ET · Ratings
Jasper Therapeutics Analyst Ratings
BenzingaDec 6 05:49 ET · Ratings
BMO Capital Initiates Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $63
Moomoo NewsDec 5 16:31 ET · Ratings
Express News | Jasper Therapeutics Inc - Initial Data Expected in Second Half of 2025
ReutersDec 2 16:30 ET

Comments

MARKET-TEST-DUMMY

Dec 18 05:56

👁

$Jasper Therapeutics (JSPR.US)$

Kamacho09

Oct 16 07:23

$Jasper Therapeutics (JSPR.US)$ 80??

Teo knows

Oct 14 07:35

$Jasper Therapeutics (JSPR.US)$ good time to hop in

Stock_Drift

Oct 14 07:09

Pre Market Ticks. 8:07am 10/14

$Destiny Tech100 (DXYZ.US)$ $Vanda Pharmaceuticals (VNDA.US)$ $In8bio (INAB.US)$ $Rani Therapeutics (RANI.US)$ $Jasper Therapeutics (JSPR.US)$ $B Riley Financial Inc 7.5% Sr Nts 31/05/2027 Usd25 (RILYZ.US)$ $B. Riley Financial Inc (RILYP.US)$ $B Riley Financial Inc 6.375% Senior Notes Due 2025 (RILYM.US)$ $B. Riley Financial (RILY.US)$ $Longboard Pharmaceuticals(Delisted) (LBPH.US)$ $Expion360 (XPON.US)$ $Inventiva (IVA.US)$ $Tevogen Bio Holdings (TVGN.US)$

Jaguar8

Oct 14 06:57

NEWS

$Jasper Therapeutics (JSPR.US)$
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
14 of 15 participants enrolled achieved a clinical response
10 of 12 participants in the 120mg cohort achieved a complete response
No serious adverse events; no grade 3 or higher adverse events reported
Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort
Company to host conference call and webinar today at 8:00 ...

Heat List

Overall

No Data